美国血液学学会第五十七次会议上的报告综述

文献来源: Ecancermedicalscience.
技术资料下载地址: http://www.ncbi.nlm.nih.gov/pubmed/26823681

Orlando Magic: report from the 57th meeting of the American Society of Haematology, 5-7 December 2015, Orlando, USA.
The 57th American Society of Haematology (ASH) meeting held in Orlando, FL was certainly the year when myeloma management changed for good, with a plethora of newly Food and Drug Administration (FDA)-approved drugs showing impressive outcome improvements and the introduction of new techniques for disease monitoring. Also, chimeric antigen receptor (CAR) T cells continued their triumphal march, consolidating their success in lymphoma and chronic lymhocytic leukaemia (CLL) and venturing into new fields such as again multiple myeloma. Some experimental drugs showed long-awaited results (midostaurin in FLT3-mutated acute myeloid leukaemia (AML)) and some brand new drugs showed promising results in the clinic after extensive preclinical studies, such as those targeting new epigenetic factors (histone methyltransferases) and apoptosis.
KEYWORDS: leukemia; lymphoma; myeloma

美国血液学学会第五十七次会议上的报告综述
57届美国血液学年会在奥兰多举行，随着大量新的食品和药物管理局（FDA）批准的药物表现出令人印象深刻的结果、改进和疾病监测新技术的引进，本年是骨髓瘤管理变好的一年。另外，嵌合抗原受体（CAR）的T细胞也继续变现出他们的成功，除了巩固其在淋巴瘤和慢性淋巴细胞白血病（CLL）的效果，也成功进入了多发性骨髓瘤等新领域。此外，一些实验性药物显示了期待已久的结果（如米哚妥林对FLT3突变的急性髓细胞性白血病（AML）），在临床上经过广泛的临床前研究，一些全新的药物显示出可喜的成果，例如针对新的表观遗传因素（组蛋白甲基转移酶）和细胞凋亡的药物。

分享出自爱康得生物技术